Quest Diagnostics Incorporated [NYSE: DGX] stock went on an upward path that rose over 1.33% on Tuesday, amounting to a one-week price decrease of less than -0.51%. The company report on November 3, 2020 that Quest Diagnostics To Speak At The Credit Suisse 29th Annual Virtual Healthcare Conference.
Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it is scheduled to speak at the Credit Suisse 29th Annual Virtual Healthcare Conference. Steve Rusckowski, Chairman, President & CEO will discuss the company’s vision, goals and two-point strategy to accelerate growth and drive operational excellence, and the company’s current perspective on the impact of the COVID-19 pandemic. The presentation is scheduled for Tuesday, November 10, 2020 at 11:45 a.m. Eastern Time.
The presentation will be webcast live during the conference and will be available on the company’s investor relations page which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 48 hours after the conclusion of the live event and will remain available until December 10, 2020.
Over the last 12 months, DGX stock rose by 25.07%. The one-year Quest Diagnostics Incorporated stock forecast points to a potential upside of 10.8. The average equity rating for DGX stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $17.16 billion, with 135.00 million shares outstanding and 134.10 million shares in the current float. Compared to the average trading volume of 1.27M shares, DGX stock reached a trading volume of 1241670 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Quest Diagnostics Incorporated [DGX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DGX shares is $141.81 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DGX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Argus have made an estimate for Quest Diagnostics Incorporated shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 21, 2020. The new note on the price target was released on July 29, 2020, representing the official price target for Quest Diagnostics Incorporated stock. Previously, the target price had yet another raise to $142, while BofA Securities analysts kept a Buy rating on DGX stock. On June 09, 2020, analysts increased their price target for DGX shares from 90 to 120.
The Average True Range (ATR) for Quest Diagnostics Incorporated is set at 3.19, with the Price to Sales ratio for DGX stock in the period of the last 12 months amounting to 2.05. The Price to Book ratio for the last quarter was 2.67, with the Price to Cash per share for the same quarter was set at 11.83. Price to Free Cash Flow for DGX in the course of the last twelve months was 15.73 with Quick ratio for the last quarter at 1.30.
DGX Stock Performance Analysis:
Quest Diagnostics Incorporated [DGX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.51. With this latest performance, DGX shares gained by 9.63% in over the last four-week period, additionally plugging by 17.77% over the last 6 months – not to mention a rise of 25.07% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DGX stock in for the last two-week period is set at 64.59, with the RSI for the last a single of trading hit 64.22, and the three-weeks RSI is set at 61.34 for Quest Diagnostics Incorporated [DGX]. The present Moving Average for the last 50 days of trading for this stock 116.15, while it was recorded at 124.28 for the last single week of trading, and 110.86 for the last 200 days.
Insight into Quest Diagnostics Incorporated Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Quest Diagnostics Incorporated [DGX] shares currently have an operating margin of +15.79 and a Gross Margin at +34.02. Quest Diagnostics Incorporated’s Net Margin is presently recorded at +10.81.
Return on Total Capital for DGX is now 11.89, given the latest momentum, and Return on Invested Capital for the company is 8.95. Return on Equity for this stock inclined to 15.38, with Return on Assets sitting at 7.00. When it comes to the capital structure of this company, Quest Diagnostics Incorporated [DGX] has a Total Debt to Total Equity ratio set at 96.01. Additionally, DGX Total Debt to Total Capital is recorded at 48.98, with Total Debt to Total Assets ending up at 42.17. Long-Term Debt to Equity for the company is recorded at 77.63, with the Long-Term Debt to Total Capital now at 39.60.
Reflecting on the efficiency of the workforce at the company, Quest Diagnostics Incorporated [DGX] managed to generate an average of $17,766 per employee. Receivables Turnover for the company is 7.44 with a Total Asset Turnover recorded at a value of 0.65.Quest Diagnostics Incorporated’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.40.
DGX Stock EPS
With the latest financial reports released by the company, Quest Diagnostics Incorporated posted 1.67/share EPS, while the average EPS was predicted by analysts to be reported at 1.6/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DGX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Quest Diagnostics Incorporated go to 9.72%.
Quest Diagnostics Incorporated [DGX] Insider Position Details
There are presently around $14,908 million, or 91.60% of DGX stock, in the hands of institutional investors. The top three institutional holders of DGX stocks are: VANGUARD GROUP INC with ownership of 15,261,676, which is approximately -3.149% of the company’s market cap and around 0.50% of the total institutional ownership; BLACKROCK INC., holding 11,656,888 shares of the stock with an approximate value of $1.47 billion in DGX stocks shares; and STATE STREET CORP, currently with $844.12 million in DGX stock with ownership of nearly -2.14% of the company’s market capitalization.
Positions in Quest Diagnostics Incorporated stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 316 institutional holders increased their position in Quest Diagnostics Incorporated [NYSE:DGX] by around 15,250,878 shares. Additionally, 377 investors decreased positions by around 17,630,781 shares, while 124 investors held positions by with 84,966,023 shares. The mentioned changes placed institutional holdings at 117,847,682 shares, according to the latest SEC report filing. DGX stock had 105 new institutional investments in for a total of 4,428,827 shares, while 69 institutional investors sold positions of 1,604,239 shares during the same period.